Kevin Dawravoo
Expertise in
22
conditions

Dr. Kevin Dawravoo

Hematology | Oncology
4405 Weaver Pkwy, 
Waterman, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
20 Years of Experience
Referral may be required
Expertise in
22
conditions
4405 Weaver Pkwy, 
Waterman, IL 

Overview

Kevin Dawravoo is a Hematologist and an Oncologist practicing medicine in Waterman, Illinois. He has been practicing medicine for over 20 years.

Dr. Dawravoo is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Gallbladder Adenocarcinoma.

Dr. Dawravoo is board certified in American Board Of Internal Medicine - Hematology (Certified). He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 5 clinical trials. Dr. Dawravoo is currently accepting new patients.

Graduate Institution

Creighton University School Of Medicine, 2006.0

Residency

Loyola University Medical Center

Specialties

Hematology
Oncology

Licenses

Internal Medicine in IL

Board Certifications

American Board Of Internal Medicine - Hematology (Certified)

Fellowships

University of Illinois College of Medicine at Chicago
University of Illinois College of Medicine at Chicago

Hospital Affiliations

Northwestern Memorial Hospital
Northwestern Medicine Kishwaukee Hospital
Palos Community Hospital
Northwestern Medicine Delnor Community Hospital
Northwestern Medicine Central Dupage Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

4405 Weaver Pkwy, Waterman, IL 60555
Other Locations
Northwestern Medicine Cancer Center Warrenville
4405 Weaver Pkwy, Warrenville, IL 60555

Additional Areas of Focus

Dr. Dawravoo has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma
Anal Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy
Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug, Other
Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide
Study Phase: Phase 2
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
View 4 Less Clinical Trials

4 Total Publications

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.
High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 10, 2026
Similar Doctors
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Expertise in
25
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Referral may be required

UChicago Medicine River East

355 E. Grand Ave., 
Chicago, IL 
 (29.4 miles away)
888-824-0200
Languages Spoken:
English, Greek, Gujarati , Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Smith is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is board certified in Medical Oncology and Practicing Since2001. Dr. Smith is currently accepting new patients.

Expertise in
17
conditions
Dr. Jessica K. Altman
Hematology | Oncology
Expertise in
17
conditions
Dr. Jessica K. Altman
Hematology | Oncology
Referral may be required
Before you request
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (29.6 miles away)
866-587-4322
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jessica Altman is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Altman is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Altman is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Altman is currently accepting new patients.

Expertise in
22
conditions
Dr. Sherif M. Badawy
Hematology | Oncology
Expertise in
22
conditions
Dr. Sherif M. Badawy
Hematology | Oncology
Referral may be required

Ann & Robert H. Lurie Children's Hospital Of Chicago

225 E Chicago Ave, 
Chicago, IL 
 (29.2 miles away)
312-227-4813
Languages Spoken:
English
See accepted insurances

Sherif Badawy is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Badawy is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Graft.

Frequently Asked Questions about Dr. Kevin Dawravoo

How do I make an appointment with Dr. Kevin Dawravoo?

You can book an appointment with Dr. Kevin Dawravoo by calling their office at 815-334-5566. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kevin Dawravoo a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kevin Dawravoo is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kevin Dawravoo specialize in?

While Dr. Kevin Dawravoo is a Hematology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kevin Dawravoo participate in research or clinical trials?

Yes. Dr. Kevin Dawravoo has published 4 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Kevin Dawravoo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kevin Dawravoo accept my insurance?

Dr. Kevin Dawravoo accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 815-334-5566 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dawravoo's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 94 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile